 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...178179180181182183184185186187188...235236» |
- | Opdivo (nivolumab) / BMS
New P2 trial: RELATIVITY-060: An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers (clinicaltrials.gov) - Sep 6, 2018
P2, N=250, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- | AiTan (rivoceranib) / HLB Bio Group
Trial initiation date, Trial primary completion date, Metastases: XHZL: Safety and Efficacy Study of Chemotherapy Plus Apatinib as Second-line Therapy in Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 6, 2018
P2, N=50, Not yet recruiting, Sponsor: Wuhan Union Hospital, China
Initiation date: Dec 2017 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2020
- | Trial completion date, Trial primary completion date: A Novel "Pediatric-Inspired" Regimen with Reduced Myelosuppressive Drugs for Adults (aged 18-60) with Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 5, 2018
P2, N=39, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Initiation date: Dec 2017 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2020 Trial completion date: Aug 2018 --> Aug 2019 | Trial primary completion date: Aug 2018 --> Aug 2019
- | Vectibix (panitumumab) / Amgen
Trial primary completion date: PANIRINOX: Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - Sep 5, 2018
P2, N=209, Recruiting, Sponsor: UNICANCER
Trial completion date: Aug 2018 --> Aug 2019 | Trial primary completion date: Aug 2018 --> Aug 2019 Trial primary completion date: Jun 2018 --> Dec 2020
- | varlitinib (ASLAN001) / ASLAN Pharma
Enrollment closed, Combination therapy, Metastases: Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line) (clinicaltrials.gov) - Sep 5, 2018
P2/3, N=40, Active, not recruiting, Sponsor: Aslan Pharmaceuticals
Trial primary completion date: Jun 2018 --> Dec 2020 Recruiting --> Active, not recruiting
- | Phase classification, Surgery: Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer (clinicaltrials.gov) - Sep 4, 2018
P1, N=23, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Recruiting --> Active, not recruiting Phase classification: P=N/A --> P1
- | pimurutamab (HLX07) / Fosun Pharma
Enrollment open, Metastases: HLX07Ib/II: The Safety,Efficacy of Anti-EGFR Humanized Monoclonal Antibody Combined With Chemotherapy in Advanced Solid Tumors. (clinicaltrials.gov) - Sep 4, 2018
P1/2, N=90, Recruiting, Sponsor: Shanghai Henlius Biotech
Phase classification: P=N/A --> P1 Not yet recruiting --> Recruiting
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date: A Study on the Timing of FOLFOX for Patients With Operable, Node Positive Rectal Cancer (clinicaltrials.gov) - Aug 31, 2018
P2, N=180, Active, not recruiting, Sponsor: Sir Mortimer B. Davis - Jewish General Hospital
Not yet recruiting --> Recruiting Trial primary completion date: May 2018 --> Dec 2020
- | Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: NEPAFOX: Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma (clinicaltrials.gov) - Aug 31, 2018
P2/3, N=40, Active, not recruiting, Sponsor: Krankenhaus Nordwest
Trial primary completion date: May 2018 --> Dec 2020 Recruiting --> Active, not recruiting | N=126 --> 40 | Trial completion date: Jun 2020 --> Jan 2019 | Trial primary completion date: Jun 2019 --> Jan 2019
- | Trial completion date: MORPHEUS-PDAC: A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) (clinicaltrials.gov) - Aug 31, 2018
P1/2, N=205, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | N=126 --> 40 | Trial completion date: Jun 2020 --> Jan 2019 | Trial primary completion date: Jun 2019 --> Jan 2019 Trial completion date: Apr 2020 --> Sep 2020
- | Erbitux (cetuximab) / Eli Lilly
Biomarker, Trial initiation date, Monotherapy, Metastases: Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC (clinicaltrials.gov) - Aug 29, 2018
P2/3, N=200, Not yet recruiting, Sponsor: Ruijin Hospital
Trial completion date: Apr 2020 --> Sep 2020 Initiation date: Nov 2016 --> Nov 2018
- | Erbitux (cetuximab) / Eli Lilly
Enrollment closed, Trial primary completion date, Metastases: Nordic 8 - A Phase II Trial (clinicaltrials.gov) - Aug 27, 2018
P2, N=180, Active, not recruiting, Sponsor: Per Pfeiffer
Initiation date: Nov 2016 --> Nov 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Aug 2019
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P2 trial, IO biomarker: AIO-STO-0417: Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer (clinicaltrials.gov) - Aug 26, 2018
P2, N=118, Not yet recruiting, Sponsor: IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest
- | Farydak (panobinostat) / Secura Bio
Trial completion date, Trial primary completion date, Combination therapy: Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Aug 24, 2018
P1, N=36, Recruiting, Sponsor: St. Jude Children's Research Hospital
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Aug 2019 Trial completion date: Aug 2019 --> Aug 2020 | Trial primary completion date: Aug 2019 --> Aug 2020
- | veliparib (ABT-888) / AbbVie, Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Metastases: NRG-GI002: Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer (clinicaltrials.gov) - Aug 24, 2018
P2, N=348, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Aug 2019 --> Aug 2020 | Trial primary completion date: Aug 2019 --> Aug 2020 Suspended --> Recruiting
- | epacadostat (INCB024360) / Incyte
Trial completion date, Trial initiation date, Trial primary completion date: Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer (clinicaltrials.gov) - Aug 24, 2018
P1/2, N=57, Not yet recruiting, Sponsor: Washington University School of Medicine
Suspended --> Recruiting Trial completion date: Feb 2022 --> May 2022 | Initiation date: Jul 2018 --> Oct 2018 | Trial primary completion date: Feb 2022 --> May 2022
- | Avastin (bevacizumab) / Roche
Trial completion, Enrollment change, Combination therapy: FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer (clinicaltrials.gov) - Aug 22, 2018
P1/2, N=50, Completed, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Trial completion date: Feb 2022 --> May 2022 | Initiation date: Jul 2018 --> Oct 2018 | Trial primary completion date: Feb 2022 --> May 2022 Active, not recruiting --> Completed | N=35 --> 50
- | NN1213 / Novo Nordisk
Trial completion, Trial primary completion date: A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma (clinicaltrials.gov) - Aug 22, 2018
P2, N=44, Completed, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Active, not recruiting --> Completed | N=35 --> 50 Recruiting --> Completed | Trial primary completion date: Apr 2018 --> Apr 2017
- | varlitinib (ASLAN001) / ASLAN Pharma
Trial completion date, Trial primary completion date, Combination therapy: ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin (clinicaltrials.gov) - Aug 22, 2018
P1, N=18, Recruiting, Sponsor: National Cancer Centre, Singapore
Recruiting --> Completed | Trial primary completion date: Apr 2018 --> Apr 2017 Trial completion date: Jun 2018 --> Jun 2020 | Trial primary completion date: Jun 2018 --> Jun 2020
- | rosmantuzumab (OMP-131R10) / Mereo Biopharma
Trial completion, Combination therapy, Metastases: A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 (clinicaltrials.gov) - Aug 22, 2018
P1, N=50, Completed, Sponsor: OncoMed Pharmaceuticals, Inc.
Trial completion date: Jun 2018 --> Jun 2020 | Trial primary completion date: Jun 2018 --> Jun 2020 Active, not recruiting --> Completed
- | Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Enrollment change, Trial withdrawal, Combination therapy, Metastases: CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Aug 22, 2018
P2, N=0, Withdrawn, Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
Active, not recruiting --> Completed N=33 --> 0 | Not yet recruiting --> Withdrawn
- | Avastin (bevacizumab) / Roche
New P2 trial, Metastases: A Study of Bevacizumab, Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (A-FOLFOXIRI) Compared With Bevacizumab, Infusional Fluorouracil, Leucovorin, and Irinotecan/Oxaliplatin (A-FOLFIRI/FOLFOX) as First-line Treatment for Metastatic Right-sided Colon Cancer (clinicaltrials.gov) - Aug 21, 2018
P2, N=120, Not yet recruiting, Sponsor: Yonsei University
- | Oncaspar liquid (pegaspargase) / Servier
Trial completion date: Treatment of Acute Lymphoblastic Leukemia in Children (clinicaltrials.gov) - Aug 21, 2018
P3, N=800, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
N=33 --> 0 | Not yet recruiting --> Withdrawn Trial completion date: Jun 2018 --> Jun 2019
- | Avastin (bevacizumab) / Roche
Trial completion, Metastases: Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer (clinicaltrials.gov) - Aug 21, 2018
P2, N=247, Completed, Sponsor: Eastern Cooperative Oncology Group
Trial completion date: Jun 2018 --> Jun 2019 Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche
Enrollment change, Trial withdrawal: DCE-MRI PET Bevacizumab Study in Rectal Cancer (clinicaltrials.gov) - Aug 21, 2018
P2, N=0, Withdrawn, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Active, not recruiting --> Completed N=30 --> 0 | Active, not recruiting --> Withdrawn
- | Trial completion date, Trial primary completion date: Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma (clinicaltrials.gov) - Aug 21, 2018
P2, N=28, Recruiting, Sponsor: Yale University
N=30 --> 0 | Active, not recruiting --> Withdrawn Trial completion date: Apr 2022 --> Aug 2022 | Trial primary completion date: Apr 2019 --> Feb 2022
- | New P1/2 trial, Metastases: Neoadjuvant Therapy Followed by Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Aug 20, 2018
P1/2, N=30, Recruiting, Sponsor: University of Alabama at Birmingham
- |||||||||| Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen
New P3 trial: CR-SEQUENCE: Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer (clinicaltrials.gov) - Aug 17, 2018
P3, N=370, Not yet recruiting, Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
- | PledOx (calmangafodipir) / PledPharma, Solasia
Clinical, P2 data, Journal: Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx(®)): a placebo-controlled randomised phase II study (PLIANT). (Pubmed Central) - Aug 17, 2018
P2
Trial completion date: Apr 2022 --> Aug 2022 | Trial primary completion date: Apr 2019 --> Feb 2022 Calmangafodipir at a dose of 5 µmol/kg appears to prevent the development of oxaliplatin-induced acute and delayed CIPN without apparent influence on tumour outcomes.
- | Trial completion date, Metastases: Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov) - Aug 16, 2018
P2, N=58, Active, not recruiting, Sponsor: University of Florida
Calmangafodipir at a dose of 5 µmol/kg appears to prevent the development of oxaliplatin-induced acute and delayed CIPN without apparent influence on tumour outcomes. Trial completion date: Jul 2018 --> Jan 2019
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Maintenance Chemotherapy After Neoadjuvant Chemoradiation Therapy for Distal Rectal Cancer (clinicaltrials.gov) - Aug 16, 2018
P2, N=5, Terminated, Sponsor: Marks, John, M.D.
Trial completion date: Jul 2018 --> Jan 2019 N=35 --> 5 | Recruiting --> Terminated | Trial completion date: Aug 2017 --> Mar 2017 | Trial primary completion date: Aug 2017 --> Mar 2017; Re-eval of patient population
- | Enrollment closed, Trial completion date, Trial primary completion date: Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma (clinicaltrials.gov) - Aug 16, 2018
P2, N=30, Active, not recruiting, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
N=35 --> 5 | Recruiting --> Terminated | Trial completion date: Aug 2017 --> Mar 2017 | Trial primary completion date: Aug 2017 --> Mar 2017; Re-eval of patient population Recruiting --> Active, not recruiting | Trial completion date: Jan 2018 --> Dec 2018 | Trial primary completion date: Jan 2018 --> Oct 2018
- | Avastin (bevacizumab) / Roche
Trial primary completion date, Metastases: Study of Vitamin D in Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 14, 2018
P2, N=120, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting | Trial completion date: Jan 2018 --> Dec 2018 | Trial primary completion date: Jan 2018 --> Oct 2018 Trial primary completion date: Mar 2018 --> Dec 2018
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma (clinicaltrials.gov) - Aug 14, 2018
P2, N=66, Recruiting, Sponsor: Case Comprehensive Cancer Center
Trial primary completion date: Mar 2018 --> Dec 2018 Trial completion date: Oct 2018 --> Apr 2019 | Trial primary completion date: Oct 2018 --> Apr 2019
- | Trial completion date, Trial primary completion date: OPRA: Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management (clinicaltrials.gov) - Aug 10, 2018
P2, N=300, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Oct 2018 --> Apr 2019 | Trial primary completion date: Oct 2018 --> Apr 2019 Trial completion date: Nov 2018 --> Nov 2019 | Trial primary completion date: Nov 2018 --> Nov 2019
- | Enrollment open: QUILT-3.080: NANT Pancreatic Cancer Vaccine (clinicaltrials.gov) - Aug 10, 2018
P1b/2, N=173, Recruiting, Sponsor: NantKwest, Inc.
Trial completion date: Nov 2018 --> Nov 2019 | Trial primary completion date: Nov 2018 --> Nov 2019 Not yet recruiting --> Recruiting
- | Enrollment open, Metastases: QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine (clinicaltrials.gov) - Aug 10, 2018
P1/2, N=382, Recruiting, Sponsor: NantKwest, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Avastin (bevacizumab) / Roche
Trial completion date, Trial primary completion date: Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer (clinicaltrials.gov) - Aug 9, 2018
P1, N=30, Active, not recruiting, Sponsor: City of Hope Medical Center
Not yet recruiting --> Recruiting Trial completion date: Sep 2018 --> Sep 2019 | Trial primary completion date: Sep 2018 --> Sep 2019
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., sorafenib / Generic mfg.
Trial completion date, Combination therapy, Metastases: Sorafenib + mFOLFOX for Hepatocellular Carcinoma (clinicaltrials.gov) - Aug 9, 2018
P2, N=40, Active, not recruiting, Sponsor: Massachusetts General Hospital
Trial completion date: Sep 2018 --> Sep 2019 | Trial primary completion date: Sep 2018 --> Sep 2019 Trial completion date: Dec 2018 --> Dec 2019
- | NN1213 / Novo Nordisk
Trial primary completion date, Surgery, Metastases: CAOAROAIO-12: Induction Chemotherapy Before or After Preoperative Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer (clinicaltrials.gov) - Aug 9, 2018
P2, N=311, Active, not recruiting, Sponsor: Prof. Dr. med. Claus R
Trial completion date: Dec 2018 --> Dec 2019 Trial primary completion date: Jun 2018 --> Sep 2018
- | IMM-101 / Immodulon
Enrollment change: Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer (clinicaltrials.gov) - Aug 9, 2018
P1/2, N=2, Terminated, Sponsor: Immodulon Therapeutics Ltd
Trial primary completion date: Jun 2018 --> Sep 2018 N=300 --> 2
- || Vectibix (panitumumab) / Amgen
Enrollment closed, Trial completion date: FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI) (clinicaltrials.gov) - Aug 7, 2018
P2, N=93, Active, not recruiting, Sponsor: AIO-Studien-gGmbH
N=300 --> 2 Recruiting --> Active, not recruiting | Trial completion date: Dec 2017 --> Jan 2022
- | Enrollment open, Metastases: Totally Neoadjuvant FOLFOXIRI + Short-course Radiation + XELOX in Patients With Locally Advanced Rectal Cancer (clinicaltrials.gov) - Aug 7, 2018
P2, N=30, Recruiting, Sponsor: China Medical University, China
Recruiting --> Active, not recruiting | Trial completion date: Dec 2017 --> Jan 2022 Not yet recruiting --> Recruiting
- | New P1/2 trial: IPLUS: Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6 (clinicaltrials.gov) - Aug 7, 2018
P1/2, N=43, Recruiting, Sponsor: Seoul National University Bundang Hospital
- | Rubraca (rucaparib) / Pharma& Schweiz, Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Trial completion date, Trial initiation date, BRCA Biomarker, PARP Biomarker, Metastases: Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer (clinicaltrials.gov) - Aug 6, 2018
P2, N=110, Not yet recruiting, Sponsor: Academic and Community Cancer Research United
Not yet recruiting --> Recruiting Trial completion date: Dec 2021 --> Dec 2022 | Initiation date: May 2018 --> Aug 2018
- | spartalizumab (PDR001) / Novartis
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Combination therapy, Metastases: PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer (clinicaltrials.gov) - Aug 3, 2018
P1, N=1, Terminated, Sponsor: Novartis Pharmaceuticals
Trial completion date: Dec 2021 --> Dec 2022 | Initiation date: May 2018 --> Aug 2018 N=92 --> 1 | Trial completion date: Jun 2019 --> Jan 2018 | Recruiting --> Terminated | Trial primary completion date: Jun 2019 --> Jan 2018; The study was terminated early due to company decision.
- | Trial completion date, Metastases: FLOT4: 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer (clinicaltrials.gov) - Aug 2, 2018
P2/3, N=716, Active, not recruiting, Sponsor: Krankenhaus Nordwest
N=92 --> 1 | Trial completion date: Jun 2019 --> Jan 2018 | Recruiting --> Terminated | Trial primary completion date: Jun 2019 --> Jan 2018; The study was terminated early due to company decision. Trial completion date: Jun 2017 --> Sep 2018
- | bemarituzumab (AMG 552) / Amgen
Enrollment closed, Enrollment change, Trial completion date, Metastases: FIGHT: A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer (clinicaltrials.gov) - Aug 2, 2018
P1a, N=10, Active, not recruiting, Sponsor: Five Prime Therapeutics, Inc.
Trial completion date: Jun 2017 --> Sep 2018 Recruiting --> Active, not recruiting | N=21 --> 10 | Trial completion date: Jun 2018 --> Feb 2019
- | Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy: Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma (clinicaltrials.gov) - Aug 1, 2018
P2, N=6, Completed, Sponsor: University of Miami
Recruiting --> Active, not recruiting | N=21 --> 10 | Trial completion date: Jun 2018 --> Feb 2019 Recruiting --> Completed | N=26 --> 6 | Trial completion date: Jun 2021 --> Jun 2018 | Trial primary completion date: Jun 2020 --> Jun 2018
- | oxaliplatin / Generic mfg.
Enrollment open: METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin (clinicaltrials.gov) - Jul 31, 2018
P2, N=100, Recruiting, Sponsor: University Hospital, Akershus
Recruiting --> Completed | N=26 --> 6 | Trial completion date: Jun 2021 --> Jun 2018 | Trial primary completion date: Jun 2020 --> Jun 2018 Not yet recruiting --> Recruiting